» Articles » PMID: 32820006

Chromatin Activation As a Unifying Principle Underlying Pathogenic Mechanisms in Multiple Myeloma

Abstract

Multiple myeloma (MM) is a plasma cell neoplasm associated with a broad variety of genetic lesions. In spite of this genetic heterogeneity, MMs share a characteristic malignant phenotype whose underlying molecular basis remains poorly characterized. In the present study, we examined plasma cells from MM using a multi-epigenomics approach and demonstrated that, when compared to normal B cells, malignant plasma cells showed an extensive activation of regulatory elements, in part affecting coregulated adjacent genes. Among target genes up-regulated by this process, we found members of the NOTCH, NF-kB, MTOR signaling, and TP53 signaling pathways. Other activated genes included sets involved in osteoblast differentiation and response to oxidative stress, all of which have been shown to be associated with the MM phenotype and clinical behavior. We functionally characterized MM-specific active distant enhancers controlling the expression of thioredoxin (), a major regulator of cellular redox status and, in addition, identified as a novel essential gene for MM. Collectively, our data indicate that aberrant chromatin activation is a unifying feature underlying the malignant plasma cell phenotype.

Citing Articles

An automated network-based tool to search for metabolic vulnerabilities in cancer.

Valcarcel L, Jose-Eneriz E, Ordonez R, Apaolaza I, Olaverri-Mendizabal D, Barrena N Nat Commun. 2024; 15(1):8685.

PMID: 39394196 PMC: 11470099. DOI: 10.1038/s41467-024-52725-4.


BET inhibitors downregulate the expression of the essential lncRNA in multiple myeloma through regulation of the transcription factor FLI1.

Gomez-Echarte N, Jose-Eneriz E, Carrasco-Leon A, Barrena N, Miranda E, Garate L Haematologica. 2024; 110(2):514-519.

PMID: 39323408 PMC: 11788633. DOI: 10.3324/haematol.2024.285966.


Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma.

Ang D, Carter J, Deka K, Tan J, Zhou J, Chen Q Nat Commun. 2024; 15(1):2513.

PMID: 38514625 PMC: 10957915. DOI: 10.1038/s41467-024-46728-4.


An atlas of cells in the human tonsil.

Massoni-Badosa R, Aguilar-Fernandez S, Nieto J, Soler-Vila P, Elosua-Bayes M, Marchese D Immunity. 2024; 57(2):379-399.e18.

PMID: 38301653 PMC: 10869140. DOI: 10.1016/j.immuni.2024.01.006.


Response of Paenibacillus polymyxa SC2 to the stress of polymyxin B and a key ABC transporter YwjA involved.

Li H, E W, Zhao D, Liu H, Pei J, Du B Appl Microbiol Biotechnol. 2024; 108(1):17.

PMID: 38170316 DOI: 10.1007/s00253-023-12916-3.


References
1.
Carvajal-Vergara X, Tabera S, Montero J, Esparis-Ogando A, Lopez-Perez R, Mateo G . Multifunctional role of Erk5 in multiple myeloma. Blood. 2005; 105(11):4492-9. DOI: 10.1182/blood-2004-08-2985. View

2.
Bommert K, Bargou R, Stuhmer T . Signalling and survival pathways in multiple myeloma. Eur J Cancer. 2006; 42(11):1574-80. DOI: 10.1016/j.ejca.2005.12.026. View

3.
Raninga P, Di Trapani G, Vuckovic S, Tonissen K . Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma. Redox Biol. 2016; 8:175-85. PMC: 4732019. DOI: 10.1016/j.redox.2016.01.007. View

4.
Kaiser M, Johnson D, Wu P, Walker B, Brioli A, Mirabella F . Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 2013; 122(2):219-26. PMC: 3709654. DOI: 10.1182/blood-2013-03-487884. View

5.
Jaitin D, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, Zaretsky I . Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science. 2014; 343(6172):776-9. PMC: 4412462. DOI: 10.1126/science.1247651. View